A new imaging platform designed to enable direct visualization of alpha-emitting radiopharmaceuticals has been introduced via a collaboration between Perceptive Discovery and MH3D, marking a significant step forward in preclinical oncology research.
The innovation, α-Sight™, addresses a longstanding challenge in radiopharmaceutical development: accurately tracking and quantifying the biodistribution of alpha-emitting therapies in vivo. While alpha therapies are gaining traction for their high precision in targeting cancer cells, limitations in imaging have historically constrained researchers’ ability to evaluate their therapeutic impact fully.
The platform integrates MH3D’s Alpha-SPECT™ Mini system with Perceptive Discovery’s expertise in imaging, radiochemistry, and quantitative analysis. This combined approach enables high-sensitivity, whole-body imaging and supports precise quantification of radiopharmaceutical distribution over time.
Powered by cadmium zinc telluride (CZT)-based detection, the system supports multi-isotope imaging and longitudinal study designs, allowing researchers to evaluate therapies such as Actinium-225 and Astatine-211 with greater accuracy. These capabilities are particularly important for understanding pharmacokinetics (PK), pharmacodynamics (PD), and tumor targeting in early-stage drug development.
A key component of the platform is its integration with advanced analytical software, enabling researchers to convert imaging data into actionable insights for decision-making. This facilitates applications including biodistribution studies, tumor targeting validation, and candidate selection, ultimately helping to de-risk radioligand therapy development programs.
As interest in targeted alpha therapies continues to grow, innovations such as α-Sight™ are expected to play a critical role in accelerating drug development by enabling more precise, data-driven evaluation of therapeutic performance. The platform reflects a broader shift toward integrating advanced imaging technologies with radiopharmaceutical research to improve outcomes in oncology.
